Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Metabolism of Abiraterone Acetate in Healthy Chinese Adults
NCT04735913Phase 1Unknown
- Sponsor
- Zhongnan Hospital of Wuhan University
- Start
- May 2020
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Abiraterone Acetate Tablets (I) in prostate cancer (PCa) (2 arms), sponsored by Zhongnan Hospital of Wuhan University. Primary endpoints: Concentrations of abiraterone in plasma at 2 months, Maximum Plasma Concentration (Cmax) at 2 months and 9 more. Status: unknown.
02
Drugs
Abiraterone Acetate Tablets (I)
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04735913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04735913.